Clinical Outcomes, Microbiological Characteristics and Risk Factors for Difficult-to-Treat Resistance to Klebsiella pneumoniae Infection

References

• Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev. 2016;80(3):629–661. doi:10.1128/mmbr.00078-15
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803–1814. doi:10.1093/cid/ciy378
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66(5):401–414. doi:10.1016/j.jinf.2012.10.028
   PubMed Web of Science ®Google Scholar
• Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38(12):1930–1945. doi:10.1007/s00134-012-2695-9
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care. 2016;20(1):221. doi:10.1186/s13054-016-1392-4
   PubMed Web of Science ®Google Scholar
• Strich JR, Kadri SS. Difficult-to-treat antibiotic-resistant gram-negative pathogens in the intensive care unit: epidemiology, outcomes, and treatment. Article. Semin Respir Crit Care Med. 2019;40(4):419–434. doi:10.1055/s-0039-1696662
   Web of Science ®Google Scholar
• Kadri SS. Recognizing the unique role of critical care providers in confronting antimicrobial resistance. Editorial. Am J Respir Crit Care Med. 2018;198(5):560–562. doi:10.1164/rccm.201805-0962ED
   Web of Science ®Google Scholar
• Huh K, Chung DR, Ha YE, et al. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. Article. Clin Infect Dis. 2020;71(9):E487–E496. doi:10.1093/cid/ciaa084
   PubMed Web of Science ®Google Scholar
• Giannella M, Bussini L, Pascale R, et al. Prognostic utility of the new definition of difficult-to-treat resistance among patients with gram-negative bloodstream infections. Article. Open Forum Infect Dis. 2019;6(12). doi:10.1093/ofid/ofz505
   Web of Science ®Google Scholar
• Strich JR, Warner S, Lai YL, et al. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study. Article. Lancet Infect Dis. 2020;20(10):1172–1181. doi:10.1016/S1473-3099(20)30153-5
   PubMed Web of Science ®Google Scholar
• Kadri SS, Lai YLE, Ricotta EE, et al. External validation of difficult-to-treat resistance prevalence and mortality risk in gram-negative bloodstream infection using electronic health record data from 140 US hospitals. Article. Open Forum Infect Dis. 2019;6(4). doi:10.1093/ofid/ofz110
   Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Raddatz J, et al. In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance trends, United States 2015–2017. Article. Clin Infect Dis. 2021;72(12):2112–2120. doi:10.1093/cid/ciaa381
   Web of Science ®Google Scholar
• Jean SS, Ko WC, Lu MC, Lee WS, Hsueh PR. Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020. Article. Expert Rev Anti Infect Ther. 2022;20(6):941–953. doi:10.1080/14787210.2022.2021876
   PubMed Web of Science ®Google Scholar
• Mouna H, Stylianos C, Linda H, et al. Inactivation of mgrB gene regulator and resistance to colistin is becoming endemic in carbapenem-resistant Klebsiella pneumoniae in Greece: a nationwide study from 2014 to 2017. Article. Int J Antimicrob Agents. 2020;55(4):105930. doi:10.1016/j.ijantimicag.2020.105930
   Web of Science ®Google Scholar
• Abdallah TAK, Elajez R, Ibrahim TB, Alimam AB, Omrani AS. Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections. Article. J Infect Public Health. 2021;14(11):1620–1622. doi:10.1016/j.jiph.2021.09.025
   PubMed Web of Science ®Google Scholar
• Li W, Sun G, Yu Y, et al. Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China. Clin Infect Dis. 2014;58(2):225–232. doi:10.1093/cid/cit675
   PubMed Web of Science ®Google Scholar
• Institute CaLS. Performance standards for antimicrobial susceptibility testing. 30th ed. In: CLSI Supplement M100 CLSI. Wayne, PA: Institute CaLS; 2020.
   Google Scholar
• Centers for Disease Control and Prevention. Healthcare-Associated Infections (HAIs). Antibiotic resistance patient safety atlas: phenotype definitions. 2015. Available from: https://arpsp.cdc.gov/resources/AR-PhenotypeDefinitions.pdf. Accessed 14 October 2022.
   Google Scholar
• Shon A, Bajwa R, Russo T. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4(2):107–118. doi:10.4161/viru.22718
   PubMed Web of Science ®Google Scholar
• Russo TA, Olson R, Fang CT, et al. Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from classical K. pneumoniae. J Clin Microbiol. 2018;56(9). doi:10.1128/jcm.00776-18
   PubMed Web of Science ®Google Scholar
• Tóth A, Damjanova I, Puskás E, et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis. 2010;29(7):765–769. doi:10.1007/s10096-010-0921-3
   Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(suppl_2):S196–S205. doi:10.1093/cid/ciy660
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Cai L, Zong Z. Enhanced survival of ST-11 carbapenem-resistant Klebsiella pneumoniae in the intensive care unit. Infect Control Hosp Epidemiol. 2020;41(6):740–742. doi:10.1017/ice.2020.68
   PubMed Web of Science ®Google Scholar
• Yang P, Wu Z, Liu C, et al. Clinical outcomes and microbiological characteristics of sequence type 11 Klebsiella pneumoniae infection. Front Med. 2022;9:889020. doi:10.3389/fmed.2022.889020
   Web of Science ®Google Scholar
• Lam MMC, Wick RR, Wyres KL, et al. Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in Klebsiella pneumoniae populations. Microb Genom. 2018;4(9):e000196. doi:10.1099/mgen.0.000196
   PubMed Web of Science ®Google Scholar
• Holden VI, Bachman MA. Diverging roles of bacterial siderophores during infection. Metallomics. 2015;7(6):986–995. doi:10.1039/c4mt00333k
   Web of Science ®Google Scholar
• Lawlor MS, O’Connor C, Miller VL. Yersiniabactin is a virulence factor for Klebsiella pneumoniae during pulmonary infection. Infect Immun. 2007;75(3):1463–1472. doi:10.1128/IAI.00372-06
   PubMed Web of Science ®Google Scholar
• Bachman MA, Oyler JE, Burns SH, et al. Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2. Infect Immun. 2011;79(8):3309–3316. doi:10.1128/IAI.05114-11
   PubMed Web of Science ®Google Scholar
• Fostervold A, Hetland MAK, Bakksjø R, et al. A nationwide genomic study of clinical Klebsiella pneumoniae in Norway 2001–15: introduction and spread of ESBLs facilitated by clonal groups CG15 and CG307. J Antimicrob Chemother. 2022;77(3):665–674. doi:10.1093/jac/dkab463
   Web of Science ®Google Scholar
• Cienfuegos-Gallet AV, Zhou Y, Ai W, Kreiswirth BN, Yu F, Chen L. Multicenter genomic analysis of carbapenem-resistant Klebsiella pneumoniae from Bacteremia in China. Microbiol Spectr. 2022;10(2):e0229021. doi:10.1128/spectrum.02290-21
   PubMed Web of Science ®Google Scholar
• Sherif M, Palmieri M, Mirande C, et al. Whole-genome sequencing of Egyptian multidrug-resistant Klebsiella pneumoniae isolates: a multi-center pilot study. Eur J Clin Microbiol Infect Dis. 2021;40(7):1451–1460. doi:10.1007/s10096-021-04177-7
   PubMed Web of Science ®Google Scholar
• Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA, Camilli A. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (Hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun. 2015;83(8):3325–3333. doi:10.1128/iai.00430-15
   PubMed Web of Science ®Google Scholar
• Russo TA, Olson R, Macdonald U, et al. Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) Klebsiella pneumoniae. Infect Immun. 2014;82(6):2356–2367. doi:10.1128/IAI.01667-13
   PubMed Web of Science ®Google Scholar
• Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3). doi:10.1128/cmr.00001-19
   PubMed Web of Science ®Google Scholar
• El Fertas-Aissani R, Messai Y, Alouache S, Bakour R. Virulence profiles and antibiotic susceptibility patterns of Klebsiella pneumoniae strains isolated from different clinical specimens. Pathol Biol. 2013;61(5):209–216. doi:10.1016/j.patbio.2012.10.004
   PubMedGoogle Scholar
• Santoro A, Franceschini E, Meschiari M, et al. Epidemiology and risk factors associated with mortality in consecutive patients with bacterial bloodstream infection: impact of MDR and XDR bacteria. Article. Open Forum Infect Dis. 2020;7(11). doi:10.1093/ofid/ofaa461
   Web of Science ®Google Scholar